Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Recruiting · NCT06758700 · Interventional (participants receive a specific treatment) · Lead sponsor: Shanghai Pulmonary Hospital, Shanghai, China
View the official record on ClinicalTrials.gov →Interventions studied
Teniposide administration
What this trial is about
The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- extensive stage small cell lung cancer
- Progression after receiving at least one chemotherapy drug treatment in the past;
- ECOG score 0-1
- c-Myc-driven
- Expected survival period ≥3 months
- Age: 18-75 years old;
- The informed consent form complies with the ICH-GCP principles.
Exclusion criteria
- No measurable lesions
- Other severe and persistent diseases or organ system dysfunction;
- Women planning pregnancy or men planning family planning;
- Women who are pregnant or breastfeeding;
- Those who cannot follow the research protocol provided by the investigator.
Where it is running
1 location listed.
- Shanghai Pulmonary Hospital, Shanghai, China - Shanghai, Shanghai Municipality, China